Atrial Fibrillation Management in Emergency and ICU Settings

Immediate Assessment and Stabilization

For hemodynamically unstable patients with atrial fibrillation, the European Heart Journal recommends immediate electrical cardioversion without delay 1, 2, 3
The American College of Cardiology suggests assessing blood pressure, mental status, signs of heart failure, and evidence of end-organ hypoperfusion in patients with atrial fibrillation 1

The European Heart Journal recommends administering IV beta-blockers (metoprolol 2.5-5 mg IV over 2 minutes, repeat every 5-10 minutes up to 15 mg) or diltiazem (0.25 mg/kg IV bolus over 2 minutes, followed by 0.35 mg/kg if needed, then infusion 5-15 mg/hour) as first-line agents for rate control in hemodynamically stable patients with preserved left ventricular function 1, 5, 4
The American College of Cardiology suggests targeting a heart rate of <110 bpm at rest (lenient control) initially, with stricter control (<80 bpm) only if symptoms persist 1

The American College of Cardiology recommends initiating therapeutic anticoagulation immediately with IV unfractionated heparin (80 units/kg bolus, then 18 units/kg/hour infusion, target aPTT 1.5-2 times control) or subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg twice daily) unless contraindicated 6, 3
The European Heart Journal suggests continuing anticoagulation for a minimum of 3 weeks before cardioversion and 4 weeks after 1, 6, 4

The European Heart Journal recommends performing immediate synchronized DC cardioversion (biphasic 120-200 joules) for hemodynamically unstable patients regardless of AF duration 1, 2, 3
The American College of Cardiology suggests that cardioversion is appropriate only if AF duration is clearly <48 hours, or patient has been therapeutically anticoagulated for ≥3 weeks, or transesophageal echo excludes left atrial thrombus 6, 3, 4

The American College of Cardiology recommends using IV procainamide (15 mg/kg IV over 30-60 minutes) or IV ibutilide for rate control in patients with Wolff-Parkinson-White syndrome and pre-excited AF 2, 5, 3
The European Heart Journal suggests using IV beta-blockers as first-line agents for rate control in patients with acute coronary syndrome and atrial fibrillation, unless contraindicated 5, 3

The American College of Cardiology warns against using digoxin as sole agent for rate control in paroxysmal AF—it is ineffective 6, 3, 4
The European Heart Journal advises against using AV nodal blockers (beta-blockers, calcium channel blockers, digoxin, adenosine) in pre-excited AF/WPW syndrome 2, 5, 3